Uncoupling of the LKB1-AMPKα energy sensor pathway by growth factors and oncogenic BRAFV600E

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Esteve Puig, Rosaura ^a   Canals, Francesc ^a   Colomé, Núria ^a   Merlino, Glenn ^b   Recio, Juan Ángel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; ADENYLATE KINASE; B RAF KINASE; BIM PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE LKB1; PROTEIN MCL 1; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; RAS PROTEIN; SCATTER FACTOR; SOMATOMEDIN C; APOPTOSIS REGULATORY PROTEIN; BRAF PROTEIN, MOUSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SIGNAL PEPTIDE; STK11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL DIVISION; CELL PROLIFERATION; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; METABOLIC STRESS; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE CULTURE; TRANSGENIC MOUSE; ULTRAVIOLET IRRADIATION; ANIMAL; DRUG EFFECT; EXPERIMENTAL MELANOMA; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

MUS MUSCULUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HEPATOCYTE GROWTH FACTOR; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 62849094740     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004771     Document Type: Article

References (47)

1. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL (2007) Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 57: 555-572; quiz 573-556.
2. Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20: 2149-2182.
3. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9: 6483-6488.
4. Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122: 337-341.
5. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA (2005) Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 37: 745-749.
6. Recio JA, Noonan FP, Takayama H, Anver MR, Duray P, et al. (2002) Ink4a/ arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res 62: 6724-6730.
7. Noonan FP, Recio JA, Takayama H, Duray P, Anver MR, et al. (2001) Neonatal sunburn and melanoma in mice. Nature 413: 271-272.
8. Marignani PA (2005) LKB1, the multitasking tumour suppressor kinase. J Clin Pathol 58: 15-19.
9. Scott KD, Nath-Sain S, Agnew MD, Marignani PA (2007) LKB1 catalytically deficient mutants enhance cyclin D1 expression. Cancer Res 67: 5622-5627.
10. Zeng PY, Berger SL (2006) LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res 66: 10701-10708.
11. Spicer J, Ashworth A (2004) LKB1 kinase: master and commander of metabolism and polarity. Curr Biol 14: R383-385.
12. Williams T, Brenman JE (2008) LKB1 and AMPK in cell polarity and division. Trends Cell Biol.
13. Dorfman J, Macara IG (2008) STRAD{alpha} Regulates LKB1 Localization by Blocking Access To Importin-{alpha}, and by Association With Crm1 and Exportin-7. Mol Biol Cell.
14. Boudeau J, Scott JW, Resta N, Deak M, Kieloch A, et al. (2004) Analysis of the LKB1-STRAD-MO25 complex. J Cell Sci 117: 6365-6375.
15. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99.
16. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, et al. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101: 3329-3335.
17. Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, et al. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. Embo J 23: 833-843.
18. Sapkota GP, Kieloch A, Lizcano JM, Lain S, Arthur JS, et al. (2001) Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell vrowth. J Biol Chem 276: 19469-19482.
19. Sapkota GP, Boudeau J, Deak M, Kieloch A, Morrice N, et al. (2002) Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. Biochem J 362: 481-490.
20. Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, et al. (2007) BID1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J 401: 29-38.
21. Xie Z, Dong Y, Scholz R, Neumann D, Zou MH (2008) Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 117: 952-962.
22. Song P, Xie Z, Wu Y, Xu J, Dong Y, et al. (2008) Protein kinase C zeta - dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem.
23. Boudeau J, Kieloch A, Alessi DR, Stella A, Guanti G, et al. (2003) Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers Syndrome patients. Hum Mutat 21: 172.
24. Barnes AP, Lilley BN, Pan YA, Plummer LJ, Powell AW, et al. (2007) LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell 129: 549-563.
25. Shelly M, Cancedda L, Heilshorn S, Sumbre G, Poo MM (2007) LKB1/STRAD promotes axon initiation during neuronal polarization. Cell 129: 565-577.
26. Fogarty S, Hardie DG (2008) C-terminal phosphorylation of LKB1 is not required for regulation of AMPK, BRSK1, BRSK2, or cell cycle arrest. J Biol Chem.
27. Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, et al. (2008) Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res 68: 759-766.
28. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810.
29. Fenton H, Carlile B, Montgomery EA, Carraway H, Herman J, et al. (2006) LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 14: 146-153.
30. Shen Z, Wen XF, Lan F, Shen ZZ, Shao ZM (2002) The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res 8: 2085-2090.
31. Avizienyte E, Loukola A, Roth S, Hemminki A, Tarkkanen M, et al. (1999) LKB1 somatic mutations in sporadic tumors. Am J Pathol 154: 677-681.
32. Rowan A, Bataille V, MacKie R, Healy E, Bicknell D, et al. (1999) Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas. J Invest Dermatol 112: 509-511.
33. Recio JA, Merlino G (2002) Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 21: 1000-1008.
34. Leshem Y, Gitelman I, Ponzetto C, Halevy O (2002) Preferential binding of Grb2 or phosphatidylinositol 3-kinase to the met receptor has opposite effects on HGF-induced myoblast proliferation. Exp Cell Res 274: 288-298.
35. Trusolino L, Bertotti A, Comoglio PM (2001) A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 107: 643-654.
36. Dokladda K, Green KA, Pan DA, Hardie DG (2005) PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway. FEBS Lett 579: 236-240.
37. Davies SP, Helps NR, Cohen PT, Hardie DG (1995) 59-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett 377: 421-425.
38. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, et al. (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282: 32539-32548.
39. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, et al. (2006) Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 281: 32207-32216.
40. Sheridan C, Brumatti G, Martin SJ (2008) Oncogenic B-RAFV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem.
41. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, et al. (2007) Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 13: 4934-4942.
42. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, et al. (2008) Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 412: 211-221.
43. Melnikova VO, Santamaria AB, Bolshakov SV, Ananthaswamy HN (2003) Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase. Oncogene 22: 5958-5966.
44. Persons DL, Yazlovitskaya EM, Pelling JC (2000) Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275: 35778-35785.
45. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, et al. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293.
46. Marani M, Hancock D, Lopes R, Tenev T, Downward J, et al. (2004) Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene 23: 2431-2441.
47. Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, et al. (2008) Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 6: 42-52.